Noninferiority of subcutaneous nivolumab to IV Opdivo was shown for the time-averaged serum concentration over the first 28 days, with a geometric mean ratio of 2.098.

Opdivo, Bristol Myers’ PD-1 immune checkpoint inhibitor, was initially approved in 2014 to treat patients (IV-ly) with unresectable or metastatic melanoma and disease progression following ...

Currently, Opdivo is approved in an intravenous (IV) form, which involves administering the drug to a vein over a period of time. The subcutaneous method can be done quicker compared with IV treatment ...

Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) ;Opdivo for ...

US Food and Drug Administration approves Opdivo® (nivolumab) as adjuvant treatment for eligible patients with completely resected stage IIB or stage IIC melanoma. Bristol Myers Squibb. October 13 ...

U.S. Food and Drug Administration Approves Opdivo ... 668 patients were randomized to receive Opdivo plus Yervoy IV infusion (Opdivo 1mg/kg with Yervoy 3mg/kg every three weeks for up to four ...

Bristol Myers Squibb (NYSE:BMY) announced Saturday that its checkpoint inhibitors Opdivo and Yervoy, when combined, reduced the risk of disease progression or death by 38% in a Phase 3 trial for ...

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC). These adult patients ...

New Subcutaneous Formulation of OPDIVO® Approved in Canada for Use Across All ... I've seen how time-consuming IV treatments can be for patients and families—especially when treatment ...

PRINCETON, N.J., February 19, 2025--BMS Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant ...

Oct 19 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Thursday the injectable form of its blockbuster cancer drug Opdivo met the main goal in trial that had patients with a type ...

Medicare Part B covers 80% of the costs when a doctor administers Opdivo as an outpatient treatment. Medicare Part D does not offer coverage. Learn more here.